Leuprolide Acetate Depot Formulation With Simplified Two-Container Mixing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing leuprolide acetate formulations require complex preparation and mixing steps before administration, and there is a need for a formulation that is easier to prepare and administer while maintaining stability and extended release properties.
Innovation Solution
A two-container system with a polymer solution and a drug solution of leuprolide acetate in a biocompatible solvent, which are stored separately and mixed just before use, forming an in situ depot for extended release over 1 to 6 months, requiring fewer mixing cycles and maintaining drug concentration stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If leuprolide acetate formulations are prepared using conventional methods, then the drug can be delivered effectively, but the preparation and mixing steps become complex and time-consuming
Solution Approach 1:
The formulation is divided into two separate containers: one containing the leuprolide acetate drug substance and the other containing the polymer solution. This segmentation eliminates the need for complex mixing steps during preparation, as each container is independently prepared and stored. The drug and polymer are combined only at the point of administration, significantly simplifying the manufacturing and preparation process.
Solution Approach 2:
The polymer solution is prepared in advance and stored in a ready-to-use state in one container, while the leuprolide acetate is prepared separately in another container. This preliminary preparation of both components eliminates the need for complex mixing operations during administration, as the components are already optimized for their respective roles before combination.
2Stability of the object's composition
If leuprolide acetate is stored in conventional formulations, then the drug remains stable, but the formulation requires multiple mixing cycles to achieve proper homogeneity
Solution Approach 1:
By separating the leuprolide acetate and polymer solution into different containers, the formulation maintains stable drug concentration in each component without requiring repeated mixing cycles. The drug substance remains stable in its container, and the polymer solution remains stable separately, eliminating the need for multiple mixing operations to achieve and maintain homogeneity.
Solution Approach 2:
The formulation utilizes specific concentration ranges (20% to 45% w/w leuprolide acetate) and polymer concentrations that ensure stability without requiring extensive mixing. The optimized parameters allow the components to be combined in a single mixing step while maintaining drug concentration stability and achieving proper homogeneity.
3Quantity of substance
If the formulation uses high drug concentration, then the treatment effectiveness is improved, but the formulation becomes more difficult to prepare and administer
Solution Approach 1:
The high concentration leuprolide acetate (20% to 45% w/w) is stored separately in one container, allowing the formulation to achieve effective drug dosing without complicating the administration process. The separate container system enables the high-concentration drug to be combined with the polymer solution at the point of use, maintaining ease of administration while ensuring therapeutic effectiveness.
Solution Approach 2:
The polymer solution acts as an intermediary vehicle that facilitates the administration of high-concentration leuprolide acetate. By dissolving the drug in the polymer solution at controlled concentrations, the formulation achieves both high drug delivery and ease of injection, as the polymer solution provides appropriate viscosity and flow characteristics for administration.
4Manufacturing precision
If the formulation requires extensive mixing to achieve homogeneity, then the drug distribution is improved, but the preparation time and complexity increase
Solution Approach 1:
The separate container system allows each component (leuprolide acetate and polymer solution) to be independently prepared with precise concentrations before combination. This segmentation ensures uniform drug distribution is achieved through a single, controlled mixing step rather than requiring extensive mixing operations, thereby reducing preparation time while maintaining manufacturing precision.
Solution Approach 2:
The formulation uses optimized drug concentrations (20% to 45% w/w leuprolide acetate) and polymer concentrations that facilitate rapid and uniform mixing. These parameter optimizations ensure that a single mixing cycle is sufficient to achieve homogeneous drug distribution, eliminating the need for multiple mixing steps and reducing overall preparation time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves physical and chemical stability over its shelf life, reduces mixing cycles to 30 or fewer, and forms a depot that releases leuprolide acetate consistently over the desired period, simplifying administration and ensuring effective drug delivery.
Implementation Method 1
a biodegradable polymer dissolved in a biocompatible solvent
Implementation Method 2
When contents of the first and second containers are mixed, the resulting composition is an extended-release composition
Data Source
AI summary
Liquid-liquid polymer leuprolide acetate (LA) formulations comprising a biodegradable polymer and biocompatible solvent, and methods of using the formulations.